Xencor, Inc. $XNCR Shares Newly Bought by VestGen Advisors LLC

Key Points

• VestGen Advisors initiated a stake in Xencor during the third quarter, purchasing 102,083 shares valued at approximately $2.55 million. Several other institutional investors also increased or initiated positions.
• Analysts have become more bullish, with Cantor Fitzgerald, Truist Financial, Barclays and Wedbush raising price targets. Xencor carries a consensus “Moderate Buy” rating and an average target price of $39.33.
• Xencor reported quarterly revenue of $51.22 million, well above the $18.89 million consensus estimate, while its loss of $0.29 per share was narrower than expected. Shares opened at $29.21, compared with a 12-month range of $10.38 to $33.60.

VestGen Advisors LLC bought a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 102,083 shares of the biopharmaceutical company's stock, valued at approximately $2,547,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in XNCR. GAMMA Investing LLC raised its holdings in shares of Xencor by 15.5% during the 3rd quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 572 shares in the last quarter. WINTON GROUP Ltd boosted its stake in Xencor by 1.5% in the 2nd quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company's stock worth $1,711,000 after purchasing an additional 1,534 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Xencor during the 2nd quarter worth approximately $30,000. Squarepoint Ops LLC purchased a new stake in Xencor during the 2nd quarter valued at about $459,000. Finally, Allworth Financial LP lifted its stake in Xencor by 23.2% in the 2nd quarter. Allworth Financial LP now owns 3,436 shares of the biopharmaceutical company's stock worth $55,000 after purchasing an additional 646 shares in the last quarter.

Analyst Ratings Changes

Several research firms have recently issued reports on XNCR. Cantor Fitzgerald upped their price objective on Xencor from $43.00 to $44.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Truist Financial boosted their target price on Xencor from $29.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday. Wall Street Zen raised shares of Xencor from a "strong sell" rating to a "hold" rating in a report on Saturday, August 8th. Barclays set a $45.00 price objective on Xencor and gave the stock an "overweight" rating in a research note on Monday. Finally, Wedbush raised their price target on Xencor from $30.00 to $45.00 and gave the company an "outperform" rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $39.33.

Xencor Stock Down 2.6%

NASDAQ:XNCR opened at $29.21 on Friday. Xencor, Inc. has a twelve month low of $10.38 and a twelve month high of $33.60. The firm has a market capitalization of $2.17 billion, a PE ratio of -13.46 and a beta of 0.89. The stock's 50-day simple moving average is $25.68 and its 200 day simple moving average is $16.89.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The business had revenue of $51.22 million for the quarter, compared to analyst estimates of $18.89 million. During the same quarter in the previous year, the firm posted ($0.41) earnings per share. The company's revenue for the quarter was up 17.4% on a year-over-year basis. On average, analysts anticipate that Xencor, Inc. will post -3.05 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor's research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.